Anavex Life Sciences (AVXL) Tax Provisions (2016 - 2025)
Anavex Life Sciences recorded quarterly Tax Provisions of $18000.0 in Q4 2025, up 126.87% quarter-over-quarter from -$67000.0 in Q2 2024.
Anavex Life Sciences' Tax Provisions history runs 10 years deep, the most recent figure standing at $18000.0 for Q4 2025.
- In Q4 2025, Tax Provisions changed N/A year-over-year to $18000.0; the TTM figure through Dec 2025 stood at $141000.0 (changed N/A YoY), while the FY2023 annual figure was $7000.0, down 98.04% from the prior year.
- Tax Provisions came in at $18000.0 for Q4 2025 at Anavex Life Sciences, up from -$67000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $209799.0 in Q3 2022 to a low of -$67000.0 in Q2 2024.
- A 5-year average of $47647.9 and a median of $39000.0 in 2021 frame the typical range for Tax Provisions.
- Across the five-year window, Tax Provisions soared 1553.32% in 2021 and slumped 263.41% in 2024, its largest moves.
- Anavex Life Sciences' Tax Provisions stood at $29980.0 in 2021, then tumbled by 166.71% to -$20000.0 in 2022, then soared by 525.0% to $85000.0 in 2023, then plunged by 178.82% to -$67000.0 in 2024, then surged by 126.87% to $18000.0 in 2025.
- According to Business Quant data, Tax Provisions over the past three periods registered $18000.0, -$67000.0, and $105000.0 for Q4 2025, Q2 2024, and Q1 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18,000.00 |
| Jun 30, 2024 | -67,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | 85,000.00 |
| Sep 30, 2023 | -64,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | -20,000.00 |
| Sep 30, 2022 | 209,799.00 |
| Jun 30, 2022 | 88,421.00 |
| Mar 31, 2022 | 29,800.00 |
| Dec 31, 2021 | 29,980.00 |
| Sep 30, 2021 | 142,731.00 |
| Jun 30, 2021 | 39,000.00 |
| Mar 31, 2021 | 26,988.00 |
| Dec 31, 2020 | 59,281.00 |
| Sep 30, 2020 | 8,633.00 |
| Jun 30, 2020 | 4,817.00 |
| Dec 31, 2019 | 9,214.00 |
| Sep 30, 2019 | 6,116.00 |
| Jun 30, 2019 | 19,300.00 |
| Mar 31, 2019 | 48,048.00 |
| Dec 31, 2018 | 8,717.00 |
| Sep 30, 2018 | 35,480.00 |
| Mar 31, 2018 | 27,861.00 |
| Dec 31, 2017 | 9,405.00 |
| Sep 30, 2017 | 9,127.00 |
| Jun 30, 2017 | 9,877.00 |
| Mar 31, 2017 | 9,595.00 |
| Dec 31, 2016 | 31,008.00 |
| Sep 30, 2016 | 6,000.00 |
| Jun 30, 2016 | 6,000.00 |